MAGENTIQ EYE Secures Series A Investment to Enhance AI in Gastroenterology
MAGENTIQ EYE LTD, a pioneer in AI-driven decision-support software for gastroenterology, has successfully completed its Series A funding round, marking a pivotal moment in its journey. The funding, spearheaded by aMoon, the leading Israeli health tech investment fund, aims to bolster the company's expansion and commercialization efforts in the U.S. and Europe. This financial infusion will also support continued advancements in MAGENTIQ COLO™, the company's flagship software, designed to enhance polyp detection and analysis during colonoscopies.
MAGENTIQ-COLO™, which is FDA and CE approved, significantly improves adenoma detection rates, a critical metric in gastroenterological health. The software not only detects polyps effectively but also provides real-time insights, helping healthcare professionals make informed decisions. The CE-approved version includes features that estimate polyp size and type, coupled with advanced AI-generated reports that further solidify its position as a cutting-edge tool in the medical field.
Involving global collaborators, the funding round also saw participation from notable investors such as Norgine Ventures BV from the Netherlands, Nina Capital from the EU and USA, Namarel Ventures SL from Spain, Nova Capital from Italy, as well as private investors Sake Bosch and Roon Doornink from the United States. In conjunction with this investment, Roy Wiesner from aMoon will join MAGENTIQ EYE’s board, injecting strategic insights and a wealth of experience in building successful health tech companies.
"This funding round represents a significant milestone for MAGENTIQ EYE. We are excited to welcome aMoon and Roy Wiesner to our mission," said Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE. "With aMoon's support, we are poised to accelerate innovation and market access, meeting growing demand amid our robust pipeline of trials and purchasing requests across the U.S. and Europe. Our advanced diagnostic tools will reach more physicians and patients worldwide."
Wiesner remarked on the company’s trajectory, stating, "We are delighted to partner with MAGENTIQ EYE, a leader in AI-driven colonoscopy. It stands out in terms of precision, features, and adaptable platform solutions for both gastrointestinal and laparoscopic applications. The initial commercial traction and increasing interest from strategic players are encouraging. This investment is part of aMoon’s commitment to support transformative tech solutions in healthcare that aim to significantly improve patient outcomes globally."
MAGENTIQ EYE is in the process of conducting clinical trials targeting specialized diseases of both the lower and upper gastrointestinal tracts, including ulcerative colitis, early Barrett’s esophagus dysplasia, and gastric intestinal metaplasia. Additionally, it is developing automated quality indicators for various gastrointestinal procedures. The funding obtained from this round will not only aid in the expansion and development of these capabilities but will also accelerate commercial growth through both direct sales and partnerships with industry leaders in the U.S., Europe, and beyond.
Founded in 2014, MAGENTIQ EYE has quickly established itself as a leader in AI-assisted colonoscopy, achieving some of the highest performance metrics available in the market today. With industry-wide recognition in gastroenterology circles and hundreds of procedures performed daily using MAGENTIQ-COLO™, the company is setting new standards in colonoscopy practices, ultimately saving more lives. You can learn more at www.magentiq.com.
Located in Israel, aMoon is a global venture capital fund with a primary focus on health technologies and life sciences, managing assets worth $1.3 billion. They collaborate with entrepreneurs harnessing revolutionary sciences and technologies to transform healthcare and enhance life quality. The fund is backed by a robust team of scientists, physicians, and entrepreneurs, along with a global network of investors and industry leaders, ensuring their portfolio companies connect with top centers in technology, finance, and medical research. Their Velocity fund invests from startup stage to Series A, while their Growth fund supports companies in growth phases, prior to public offerings or during critical clinical cycles.
MAGENTIQ-COLO™, which is FDA and CE approved, significantly improves adenoma detection rates, a critical metric in gastroenterological health. The software not only detects polyps effectively but also provides real-time insights, helping healthcare professionals make informed decisions. The CE-approved version includes features that estimate polyp size and type, coupled with advanced AI-generated reports that further solidify its position as a cutting-edge tool in the medical field.
Involving global collaborators, the funding round also saw participation from notable investors such as Norgine Ventures BV from the Netherlands, Nina Capital from the EU and USA, Namarel Ventures SL from Spain, Nova Capital from Italy, as well as private investors Sake Bosch and Roon Doornink from the United States. In conjunction with this investment, Roy Wiesner from aMoon will join MAGENTIQ EYE’s board, injecting strategic insights and a wealth of experience in building successful health tech companies.
"This funding round represents a significant milestone for MAGENTIQ EYE. We are excited to welcome aMoon and Roy Wiesner to our mission," said Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE. "With aMoon's support, we are poised to accelerate innovation and market access, meeting growing demand amid our robust pipeline of trials and purchasing requests across the U.S. and Europe. Our advanced diagnostic tools will reach more physicians and patients worldwide."
Wiesner remarked on the company’s trajectory, stating, "We are delighted to partner with MAGENTIQ EYE, a leader in AI-driven colonoscopy. It stands out in terms of precision, features, and adaptable platform solutions for both gastrointestinal and laparoscopic applications. The initial commercial traction and increasing interest from strategic players are encouraging. This investment is part of aMoon’s commitment to support transformative tech solutions in healthcare that aim to significantly improve patient outcomes globally."
MAGENTIQ EYE is in the process of conducting clinical trials targeting specialized diseases of both the lower and upper gastrointestinal tracts, including ulcerative colitis, early Barrett’s esophagus dysplasia, and gastric intestinal metaplasia. Additionally, it is developing automated quality indicators for various gastrointestinal procedures. The funding obtained from this round will not only aid in the expansion and development of these capabilities but will also accelerate commercial growth through both direct sales and partnerships with industry leaders in the U.S., Europe, and beyond.
Founded in 2014, MAGENTIQ EYE has quickly established itself as a leader in AI-assisted colonoscopy, achieving some of the highest performance metrics available in the market today. With industry-wide recognition in gastroenterology circles and hundreds of procedures performed daily using MAGENTIQ-COLO™, the company is setting new standards in colonoscopy practices, ultimately saving more lives. You can learn more at www.magentiq.com.
About aMoon
Located in Israel, aMoon is a global venture capital fund with a primary focus on health technologies and life sciences, managing assets worth $1.3 billion. They collaborate with entrepreneurs harnessing revolutionary sciences and technologies to transform healthcare and enhance life quality. The fund is backed by a robust team of scientists, physicians, and entrepreneurs, along with a global network of investors and industry leaders, ensuring their portfolio companies connect with top centers in technology, finance, and medical research. Their Velocity fund invests from startup stage to Series A, while their Growth fund supports companies in growth phases, prior to public offerings or during critical clinical cycles.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.